Article
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Cancer research - 1 Jan 2003
Hara Takahito, Miyazaki Jun-ichi, Araki Hideo, Yamaoka Masuo, Kanzaki Naoyuki, Kusaka Masami, Miyamoto Masaomi
Abstract excerpt
Most prostate cancers (PCs) become resistant to combined androgen blockade therapy with surgical or medical castration and antiandrogens after several years. Some of these refractory PCs regress after discontinuation of antiandrogen administration [antiandrogen withdrawal syndrome (AWS)]. Although the molecular mechanisms of the AWS are not fully understood because of the lack of suitable experimental models, one...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.